- Home
- GHRS vs FTRE Comparison
GHRS vs FTRE Comparison
Compare GHRS & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- FTRE
- Stock Information
- Founded
- GHRS 2018
- FTRE 1996
- Country
- GHRS Ireland
- FTRE United States
- Employees
- GHRS N/A
- FTRE N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- FTRE Medical Specialities
- Sector
- GHRS Health Care
- FTRE Health Care
- Exchange
- GHRS Nasdaq
- FTRE Nasdaq
- Market Cap
- GHRS 774.1M
- FTRE 864.4M
- IPO Year
- GHRS 2021
- FTRE N/A
- Fundamental
- Price
- GHRS $13.10
- FTRE $9.45
- Analyst Decision
- GHRS Strong Buy
- FTRE Hold
- Analyst Count
- GHRS 8
- FTRE 9
- Target Price
- GHRS $30.63
- FTRE $12.06
- AVG Volume (30 Days)
- GHRS 307.7K
- FTRE 1.6M
- Earning Date
- GHRS 11-13-2025
- FTRE 11-07-2025
- Dividend Yield
- GHRS N/A
- FTRE N/A
- EPS Growth
- GHRS N/A
- FTRE N/A
- EPS
- GHRS N/A
- FTRE N/A
- Revenue
- GHRS N/A
- FTRE $2,733,500,000.00
- Revenue This Year
- GHRS N/A
- FTRE N/A
- Revenue Next Year
- GHRS N/A
- FTRE N/A
- P/E Ratio
- GHRS N/A
- FTRE N/A
- Revenue Growth
- GHRS N/A
- FTRE N/A
- 52 Week Low
- GHRS $6.00
- FTRE $3.97
- 52 Week High
- GHRS $20.50
- FTRE $25.28
- Technical
- Relative Strength Index (RSI)
- GHRS 45.98
- FTRE 52.25
- Support Level
- GHRS $13.00
- FTRE $8.31
- Resistance Level
- GHRS $14.96
- FTRE $10.87
- Average True Range (ATR)
- GHRS 0.78
- FTRE 0.59
- MACD
- GHRS -0.00
- FTRE -0.14
- Stochastic Oscillator
- GHRS 28.46
- FTRE 44.64
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.